Download This Paper
Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
A Multicentre Randomised Controlled Trial Comparing Safety, Efficacy, and Cost-Effectiveness of the Surgisis® Anal Fistula Plug versus Surgeon's Preference for Transsphincteric Fistula-in-Ano: The FIAT Trial
31 Pages Posted: 17 Apr 2019
More...Abstract
Background: The Biodesign Surgisis anal fistula plug preserves continence, but its efficacy in healing anal fistulae is uncertain.
Methods: A randomised trial involving 40 UK hospitals comparing the fistula plug with surgeon's preference (advancement flap, cutting seton, fistulotomy, LIFT procedure) for cryptoglandular transsphincteric anal fistulae. Randomisation was a one-to-one, minimised by age, ASA grade, planned surgery, and presence of secondary tracts. The primary outcome was faecal incontinence quality of life (FIQoL) at 12-months. Secondary outcomes were fistula healing, incontinence rates, and complication and re-intervention rates. A trial-based cost-utility analysis was undertaken.
Findings: Between May 2011 and March 2016, 304 participants were equally randomised to fistula plug or surgeon's preference. No differences were seen in FIQoL between the two groups at 12-months. Clinical fistula healing was reported in 66/122 (54%) of the fistula plug and 66/119 (55%) of the surgeon's preference groups at 12-months. Faecal incontinence rates showed a marginal improvement in both groups. Complications and re-interventions were frequent, with significantly more complications in the fistula plug group at 6-weeks (49/142, 35% vs. 25/137, 18%; p=0.002). The mean total costs were £2,738 (s.d. £1,151) for the fistula plug and £2,308 (s.d. £1,228) for the surgeon's preference group (mean difference +£430, p=0.0174). The average total QALYs gained was marginally higher in the fistula plug group. Using multiple imputation and probabilistic sensitivity analysis the fistula plug was 35%-45% likely to be costeffective across a willingness to pay threshold of £20,000-£30,000/QALY.
Interpretation: The Biodesign Surgisis® anal fistula plug is associated with similar FIQoL and healing rates to surgeon's preference at 12-months. Higher costs and highly uncertain gains in QALYs mean that the fistula plug may not be considered as a cost-effective treatment in the UK NHS.
Trial Registration Number: (ISRCTN 78352529).
Funding Statement: The FIAT trial was funded by the NIHR Health Technology Assessment Programme - 07/89/01.
Declaration of Interests: The authors declare no competing interests.
Ethics Approval Statement: Ethical committee approval was obtained (10/H0405/29). The trial was overseen by an independent Trial Steering Committee and Data Monitoring and Ethics Committee.
Suggested Citation: Suggested Citation